Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date

Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Zavras, PD, Wang, Y, Gandhi, A, Lontos, K, Delgoffe, GM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572744/
https://www.ncbi.nlm.nih.gov/pubmed/31354288
http://dx.doi.org/10.2147/OTT.S177844
_version_ 1783427709192372224
author Zavras, PD
Wang, Y
Gandhi, A
Lontos, K
Delgoffe, GM
author_facet Zavras, PD
Wang, Y
Gandhi, A
Lontos, K
Delgoffe, GM
author_sort Zavras, PD
collection PubMed
description Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CAR T products, the financial implications for payers, and ongoing trials.
format Online
Article
Text
id pubmed-6572744
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65727442019-07-26 Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date Zavras, PD Wang, Y Gandhi, A Lontos, K Delgoffe, GM Onco Targets Ther Review Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CAR T products, the financial implications for payers, and ongoing trials. Dove 2019-06-11 /pmc/articles/PMC6572744/ /pubmed/31354288 http://dx.doi.org/10.2147/OTT.S177844 Text en © 2019 Zavras et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Zavras, PD
Wang, Y
Gandhi, A
Lontos, K
Delgoffe, GM
Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
title Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
title_full Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
title_fullStr Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
title_full_unstemmed Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
title_short Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
title_sort evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large b cell lymphoma: evidence to date
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572744/
https://www.ncbi.nlm.nih.gov/pubmed/31354288
http://dx.doi.org/10.2147/OTT.S177844
work_keys_str_mv AT zavraspd evaluatingtisagenlecleucelanditspotentialinthetreatmentofrelapsedorrefractorydiffuselargebcelllymphomaevidencetodate
AT wangy evaluatingtisagenlecleucelanditspotentialinthetreatmentofrelapsedorrefractorydiffuselargebcelllymphomaevidencetodate
AT gandhia evaluatingtisagenlecleucelanditspotentialinthetreatmentofrelapsedorrefractorydiffuselargebcelllymphomaevidencetodate
AT lontosk evaluatingtisagenlecleucelanditspotentialinthetreatmentofrelapsedorrefractorydiffuselargebcelllymphomaevidencetodate
AT delgoffegm evaluatingtisagenlecleucelanditspotentialinthetreatmentofrelapsedorrefractorydiffuselargebcelllymphomaevidencetodate

Ejemplares similares